Effect of Reduced Vasopressors on Mortality in ECMO-supported Cardiogenic Shock Patients

Launched by XIAOTONG HOU · Mar 4, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how reducing the use of vasopressors—medications that help raise blood pressure—might affect survival in adults with a serious condition called cardiogenic shock. Cardiogenic shock happens when the heart is unable to pump enough blood to meet the body's needs, and patients may require a treatment called venoarterial extracorporeal membrane oxygenation (VA-ECMO) to support their heart function. The main aim of the study is to find out if using fewer vasopressors can help improve survival rates within 30 days for these patients.

To be eligible for the trial, participants must be adults aged 18 and older who are experiencing cardiogenic shock and are starting VA-ECMO for the first time. Those with certain severe conditions or who require vasopressors for other reasons will not be included. If you or a family member participates, the study will involve collecting information about vasopressor use and health outcomes over time. This research could help doctors better understand the best treatment approaches for patients with cardiogenic shock.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults (≥18 years) with cardiogenic shock requiring VA-ECMO support.
• • First-time ECMO initiation.
• • Venoarterial ECMO (VA-ECMO) as the initial mode.
• Exclusion Criteria:
• • Age \<18 years.
• • Severe pulmonary hypertension.
• • Vasopressor use for non-shock indications (e.g., bleeding, post-cardiopulmonary bypass vasoplegia).
• • Severe missing data.